Phase 4 N=122 Contrast Nephropathy and Nitrates
Contrast Induced Nephropathy
Primary: Change in GFR — 1.8; -4.1 mL/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=120 Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification
Cataracts
Primary: Pharmacokinetics in Aqueous Humor Samples. — 443.07; 56.4525 ng/ml
Phase 4 N=50 Prospective Validation of a Plasma Transfusion Dosing Algorithm in Patients With Chronic Liver Disease
Liver Disease
Primary: Number of Participants That Reached Targeted International Normalized Ratio (INR) Within ±0.1 After First Fresh Frozen Plasma (FFP) Transfusion Completed. — 7; 17…
Phase 4 N=52 Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer
Breast Cancer
Primary: Overall Number of Participants by the Number of Serious Adverse Events Reported Per Participant — 31; 17; 14; 21 Participants
Phase 4 N=36 Treatment of Diabetes in Patients With Systolic Heart Failure
Heart Failure, Systolic · Diabetes Mellitus, Type 2
Primary: Change From Baseline Aerobic Exercise Capacity at 12 Weeks — 0.67; -0.53 mL/kg/min — p=0.083
Phase 4 N=201 A Study to Assess Menstrual Cramp Pain Associated With Primary Dysmenorrhea
Dysmenorrhea
Primary: Sum of Total Pain Relief (TOTPAR) Over 0-12 Hours — 29.18; 24.87 Scores on a scale * hours — p=< 0.001
Phase 4 N=103 Treatment of Non Alcoholic Fatty Liver Disease With n-3 Fatty Acids
Non-Alcoholic Fatty Liver Disease
Primary: Percentage of Liver Fat — -7.9; -4.6 percentage of liver fat — p=0.48
Phase 4 N=119 TBE (Tick-borne Encephalitis) Vaccination in Allergic Patients
Vaccine Responsiveness in Allergy · Vaccine Responsiveness During Allergy De-sensitization Treatment
Primary: Humoral TBE Immunity — 317.90; 250.10; 282.20 titer
Phase 4 N=134 Smoking Cessation in Hispanic Construction Workers
Smoking Cessation
Primary: Prolonged Abstinence Rates — 36.00; 30.43 Percentage of participants
Phase 4 N=6,983 World-wide Randomized Antibiotic Envelope Infection Prevention Trial
CIED Related Infection
Primary: 12 Month Kaplan-Meier Estimate of Major CIED Infection Rate — 0.7; 1.2 Percentage of subjects — p=0.0406
Phase 4 N=349 Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)
Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD
Primary: Mean Change in Best-corrected Visual Acuity (BCVA) From Baseline to 24 Months. — 3.2; 2.5 Letters — p=0.787
Phase 4 N=100 Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients
Heart Failure
Primary: Cummulative Incidence of Events at Week 26 — 35.6; 43.8 Percentage of events at 26 weeks
Phase 4 N=120 The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study
Diabetes Mellitus, Type 2 · Diabetes
Primary: Mean Change From Randomization in A1c at Week 26 — 3.4; 4.1 Percentage of glycosylated hemoglobin
Phase 4 N=110 Trigger Finger Corticosteroid Injection With and Without Local Anesthetic
Trigger Finger
Primary: Pain Outcome: Visual Analog Scale — 3.5; 2 score on a scale
Phase 4 N=350 Deep Neuromuscular Block for Laparoscopic Surgery
Laparoscopy · Anesthesia Recovery Period
Primary: Percentage of Patients Recovered Cognitively at 1 Week — 91.8; 92.9 percentage of patients recovered